Transmission Dynamics of Carbapenemase-Encoding Genes in CREC: Technical Insights from Guangdong Province (2022–2024)

Study Background and Research Question

The ongoing rise of carbapenem-resistant Enterobacteriaceae (CRE) presents a global health concern, particularly as resistance mechanisms outpace the development of new therapeutics. Within this group, Enterobacter cloacae complex (CREC) is increasingly recognized for its multidrug-resistant profiles and clinical prevalence in China. The COVID-19 pandemic has further exacerbated antimicrobial resistance trends by increasing antibiotic pressure and complicating infection control practices. However, the detailed characterization of carbapenemase-encoding genes (CEGs) and their transmission within CREC populations during the pandemic period has remained insufficiently explored. The recent reference study addresses this gap by investigating the prevalence, genetic localization, and dissemination dynamics of CEGs among CREC isolates from eight tertiary hospitals in Guangdong province between December 2022 and June 2024.

Key Innovation from the Reference Study

The principal innovation lies in the integrated genomic and epidemiological mapping of CEGs within a defined clinical and temporal context. By distinguishing between plasmid- and chromosome-associated resistance determinants and evaluating their transferability, the study clarifies how mobile genetic elements shape the rapid spread of carbapenemase genes—especially bla_NDM-1—in diverse hospital settings. This dual-level mapping, coupled with rigorous phenotypic resistance profiling, provides unprecedented resolution of the mechanisms underpinning the persistence and propagation of multidrug-resistant CREC strains during a period of heightened clinical challenge.

Methods and Experimental Design Insights

• Sample Collection: Fifty-four non-duplicate CREC isolates were gathered from eight teaching hospitals, encompassing various clinical departments and specimen types.
• Genetic Characterization: Presence and localization (plasmid versus chromosome) of CEGs—including bla_NDM-1, bla_IMP, and bla_KPC-2—were determined by PCR and variable temperature SDS plasmid elimination.
• Antimicrobial Susceptibility Testing: Broth microdilution assays quantified resistance to multiple antibiotics, enabling direct comparison between CEG-positive and -negative groups.
• Plasmid Conjugation and Transferability: Plasmid-mediated horizontal gene transfer was assessed through conjugation experiments, with success rates determined for each gene type.
• Mobile Genetic Element Typing: PCR identified six classes of mobile genetic elements, with ISEcp1 being the most prevalent.
• Genotypic Diversity: ERIC-PCR and NTSYS clustering classified isolates into 17 distinct genotypes, supporting epidemiological inference.

The comprehensive application of molecular and phenotypic assays distinguishes the study's methodological rigor, allowing direct linkage of gene presence, mobility, and clinical epidemiology.

Core Findings and Why They Matter

The study reports a high overall prevalence of CEGs (85.19%) among CREC isolates, with bla_NDM-1 as the dominant gene. Notably, 33.33% of isolates carried bla_NDM-1 on both chromosomes and plasmids, while 46.30% harbored it exclusively on plasmids. This dual localization highlights the gene’s potential for both vertical inheritance and horizontal dissemination.

Other findings include:

• Successful horizontal transfer of CEGs was observed in 95.65% of tested strains, with bla_NDM-1 and bla_IMP demonstrating particularly high transferability (95.45% and 100%, respectively), while bla_KPC-2 failed to transfer under assay conditions.
• Six types of mobile genetic elements were identified, with ISEcp1 present in 87.04% of isolates. Many isolates harbored multiple element types, reinforcing the complex genetic context facilitating gene spread.
• Multidrug resistance was significantly higher in CEG-positive strains, with elevated resistance rates to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin compared to CEG-negative strains (P<0.05).
• Genotypic profiling revealed 17 unique genotypes, with type E and G being most prevalent and distributed across several hospitals and departments, indicating inter-institutional transmission events.
• Epidemiological analysis found higher rates of CEG detection in male patients, elderly individuals, respiratory medicine wards, and sputum samples.

These findings underscore the rapid, broad, and multifaceted dissemination of carbapenem resistance in clinical settings, with significant implications for hospital infection control and antimicrobial stewardship.

Comparison with Existing Internal Articles

Several internal resources provide complementary technical perspectives on antimicrobial resistance and laboratory modeling:

• The article Transmission Dynamics of Carbapenemase Genes in CREC, China offers a broad context for understanding the genetic mobility and hospital-based transmission of CEGs, echoing the reference study’s emphasis on plasmid-mediated spread during the COVID-19 era.
• For researchers developing or optimizing bacterial infection models or dissecting resistance mechanisms, the application of third-generation cephalosporins such as cefotaxime is highlighted, supporting workflows that map Gram-positive and Gram-negative resistance traits.
• Further guidance on practical assay design and troubleshooting can be found in Advanced Workflows for Antimicrobial Resistance Research, which details best practices for reproducible resistance studies using lactamase-resistant cephalosporins.

In synthesis, the reference study and these internal resources collectively reinforce the importance of integrating molecular, epidemiological, and phenotypic data in antimicrobial resistance research, especially when modeling the dynamics of gene transfer under real-world hospital conditions.

Limitations and Transferability

Despite its comprehensive approach, the study is limited by its regional sampling frame (eight hospitals in Guangdong) and the relatively short collection period. While the findings are highly relevant for similar tertiary care settings with comparable antimicrobial use pressures, caution is warranted in extrapolating genotypic prevalence or transferability rates to other geographic or healthcare contexts. Additionally, the failure to observe bla_KPC-2 transfer in conjugation assays may reflect either methodological constraints or true biological differences in gene mobility.

Protocol Parameters

• Isolate selection: Use non-duplicate clinical isolates across departments and specimen types to capture diversity.
• CEG detection: PCR-based screening, with subsequent plasmid elimination or extraction to distinguish gene localization.
• Conjugation assay: Employ appropriate recipient strains and monitor transfer success by selectable markers or PCR confirmation.
• Antimicrobial susceptibility testing: Broth microdilution, interpreted according to current clinical breakpoints.
• Genotyping: ERIC-PCR or comparable methods, with clustering analysis for epidemiological mapping.

These parameters draw directly from the reference study and internal workflow recommendations and can be adapted to local laboratory capabilities.

Research Support Resources

Researchers working on antimicrobial resistance, gene transfer, or bacterial infection models may require high-purity, reproducible antibiotics for phenotypic assays and selection. Cefotaxime (SKU BA1012) is a third-generation cephalosporin antibiotic with proven stability against beta-lactamase enzymes and broad-spectrum efficacy, facilitating the design and validation of resistance models in both Gram-positive and Gram-negative bacteria. For optimal performance in laboratory workflows, freshly prepared solutions are recommended, as detailed in the product information. APExBIO supplies research-grade Cefotaxime suitable for these applications, supporting robust experimental design in resistance studies.